Breaking News Instant updates and real-time market news.

VRX

Ticker changed BHC

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16

Ackman might be making a comeback, Barron's says

Bill Ackman's Pershing Square Holdings has been battered by a long position in Valeant Pharmaceuticals International (VRX) and a short bet against Herbalife Nutrition (HLF), which have been both closed out, Andrew Bary writes in this week's edition of Barron's. But after a humbling three year stretch, the hedge fund titan could be making a comeback, he adds. Closed-end funds tied to Ackman's and Daniel Loeb's hedge funds offer investors an opportunity to participate in their success, Barron's notes. Reference Link

VRX

Ticker changed BHC

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

  • 01

    Aug

  • 27

    Aug

VRX Ticker changed BHC
$23.40

-0.84 (-3.47%)

06/27/18
RBCM
06/27/18
NO CHANGE
Target $25
RBCM
Sector Perform
Valeant price target raised to $25 from $19 at RBC Capital
RBC Capital analyst Douglas Miehm raised his price target on Valeant to $25, saying the company's FY18 guidance is likely to prove to be "conservative". The analyst notes the management's commentary that Q1 would mark a trough quarter as its fundamentals are improving, adding that Q2 volumes and price trends for Valeant's largest drug - Xifaxan - point to a strong Q2. Miehm keeps his Sector Perform rating however, citing the likelihood of near-term volatility around the potential delays in its Duobrii psoriasis treatment.
06/28/18
DBAB
06/28/18
NO CHANGE
DBAB
Buy
Deutsche reiterates Buy on Valeant after headquarter visit
Deutsche Bank analyst Gregg Gilbert reiterates a Buy rating on Valeant Pharmaceuticals after visiting the company's headquarters. The analyst left feeling that management is doing the right things to strengthen the business, including investing behind core growth franchises, investing in R&D to support future growth, and strengthening the balance sheet. While keeping his estimates unchanged, Gilbert is more confident in potential drivers of upside, including the growth and durability of the Xifaxan franchise and growth for the Consumer and Bausch and Lomb segments. He continues to like the stock's risk/reward.
06/29/18
MZHO
06/29/18
NO CHANGE
Target $31
MZHO
Buy
Valeant price target raised to $31 from $27 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals to $31 to reflect higher Xifaxan estimates. The analyst views the Xifaxan franchise, and not Valeant's dermatology portfolio, as the key growth driver for the company. She reiterates a Buy rating on Valeant shares.
07/13/18
EVER
07/13/18
NO CHANGE
EVER
In Line
Evercore says FDA tentatively approves generic of another top 10 Valeant drug
Evercore ISI analyst Umer Raffat notes that the FDA website shows that a generic version of Valeant's (VRX) Apriso, a top 10 product for the company, has been granted a tentative approval. This approval, which was granted to Teva (TEVA), is the second generic approval for one of the company's top 10 products in the last few days, as a generic Uceris approval was also recently granted, added Raffat in his note to investors. He maintains an In Line rating on Valeant shares.
HLF Herbalife Nutrition
$53.95

-0.14 (-0.26%)

03/05/18
SBSH
03/05/18
UPGRADE
SBSH
Buy
Herbalife Nutrition upgraded to Buy from Neutral at Citi
03/06/18
SBSH
03/06/18
UPGRADE
Target $114
SBSH
Buy
Citi sees further upside in Herbalife, upgrades shares to Buy
Citi analyst Beth Kite last night upgraded Herbalife to Buy from Neutral and raised her price target for the shares to $114 from $85. The stock in premarket trading is up 3%, or $2.98, to $97.25. Since January, the company has made capital allocation announcements, enacted several executive changes, and found out that Bill Ackman closed out his long-standing and well-publicized short position, Kite tells investors in a research note. The analyst sees further upside in the shares as Herbalife executes a tender offer and refinances its debt, to both reinvest in the business and repurchase shares in 2019. If the company can deliver its local currency sales growth guidance in 2018, it would be one of the best top line stories in Household/Personal Care Products, Kite contends.
03/06/18
03/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Hold at Stifel with analyst David Ross saying after the recent share pullback, UPS' valuation is "reasonable" considering the risks ahead and the increased capital investments expected over the next several years. 2. PPL Corp. (PPL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Shelby Tucker saying he believes that the uncertainty around the impact of RIIO-2 price controls on the company's financials has been more than discounted in the stock price, while the equity needs due to tax reform have also been digested by investors. 3. First Republic (FRC) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Keating saying he believes the impact of First Republic's "millennial strategies" on client household acquisition is underappreciated and that tax reform will not weigh the bank's businesses. 4. Herbalife Nutrition (HLF) upgraded to Buy from Neutral at Citi with analyst Beth Kite saying since January, the company has made capital allocation announcements, enacted several executive changes, and found out that Bill Ackman closed out his long-standing and well-publicized short position. 5. Mylan (MYL) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/18
RHCO
05/04/18
NO CHANGE
Target $105
RHCO
Hold
Herbalife Nutrition price target raised to $105 from $76 at SunTrust
SunTrust analyst Michael Swartz raised his price target on Herbalife to $105 following its Q1 earnings beat that also showed "improving trends in the U.S." The analyst notes however that China volume fell dramatically by 23% after last year's price increase. Swartz keeps his Hold rating on Herbalife and recommends that investors don't chase the stock price after its year-to-date gains.

TODAY'S FREE FLY STORIES

TOL

Toll Brothers

$29.87

-1.96 (-6.16%)

15:45
11/15/18
11/15
15:45
11/15/18
15:45
Options
Toll Brothers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AAPL

Apple

$190.76

3.95 (2.11%)

15:44
11/15/18
11/15
15:44
11/15/18
15:44
Periodicals
Apple partners with A24 to make feature-length movies, Variety says »

Apple is enlisting indie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$191.08

4.27 (2.29%)

15:42
11/15/18
11/15
15:42
11/15/18
15:42
Periodicals
Breaking Periodicals news story on Apple »

Apple and movie studio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTI

British American Tobacco

$34.97

-1.54 (-4.22%)

15:41
11/15/18
11/15
15:41
11/15/18
15:41
Hot Stocks
British American says menthol cigarettes should not be treated 'differently' »

In a statement regarding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:38
11/15/18
11/15
15:38
11/15/18
15:38
Hot Stocks
Breaking Hot Stocks news story  »

Greenpro Capital…

WTW

Weight Watchers

$49.93

0.91 (1.86%)

15:37
11/15/18
11/15
15:37
11/15/18
15:37
Conference/Events
Weight Watchers management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

WSM

Williams-Sonoma

$60.33

-1.43 (-2.32%)

15:34
11/15/18
11/15
15:34
11/15/18
15:34
Options
Williams Sonoma options imply 10.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

15:33
11/15/18
11/15
15:33
11/15/18
15:33
Hot Stocks
Breaking Hot Stocks news story  »

Greenpro Capital…

QLYS

Qualys

$74.55

2.63 (3.66%)

15:32
11/15/18
11/15
15:32
11/15/18
15:32
Conference/Events
Qualys management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Jan

FAST

Fastenal

$57.06

1.21 (2.17%)

15:30
11/15/18
11/15
15:30
11/15/18
15:30
Options
Timely sweep of Fastenal calls »

Timely sweep of Fastenal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.54

2.35 (0.87%)

15:28
11/15/18
11/15
15:28
11/15/18
15:28
Hot Stocks
Assistant AG Delrahim says DOJ seeks to curtail bid-rigging in gov't purchases »

Assistant Attorney…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.54

2.35 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$129.03

4.03 (3.22%)

15:27
11/15/18
11/15
15:27
11/15/18
15:27
Conference/Events
Stanley Black & Decker management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

DDS

Dillard's

$63.35

-10.28 (-13.96%)

15:27
11/15/18
11/15
15:27
11/15/18
15:27
Downgrade
Dillard's rating change  »

Dillard's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$127.24

-0.05 (-0.04%)

15:20
11/15/18
11/15
15:20
11/15/18
15:20
Options
Notable call spread in Universal Health as shares advance »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$58.79

-2.305 (-3.77%)

15:19
11/15/18
11/15
15:19
11/15/18
15:19
Options
Nordstrom options imply 9.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SPY

SPDR S&P 500 ETF Trust

$271.84

1.65 (0.61%)

, SPX

S&P 500

$0.00

(0.00%)

15:17
11/15/18
11/15
15:17
11/15/18
15:17
General news
U.S. official: China trade offer should be viewed with skepticism, Reuters says »

An unnamed U.S.…

SPY

SPDR S&P 500 ETF Trust

$271.84

1.65 (0.61%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/15/18
11/15
15:17
11/15/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/15/18
11/15
15:16
11/15/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$35.42

1.83 (5.45%)

15:04
11/15/18
11/15
15:04
11/15/18
15:04
Options
Applied Materials options imply 6.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

RMNI

Rimini Street

$5.45

0.13 (2.44%)

15:04
11/15/18
11/15
15:04
11/15/18
15:04
Hot Stocks
Rimini Street expands investment and operations in Asia-Pacific »

Rimini Street announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$273.24

3.05 (1.13%)

, SPX

S&P 500

$0.00

(0.00%)

15:03
11/15/18
11/15
15:03
11/15/18
15:03
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Ross says U.S. still…

SPY

SPDR S&P 500 ETF Trust

$273.24

3.05 (1.13%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$53.35

1.74 (3.37%)

15:00
11/15/18
11/15
15:00
11/15/18
15:00
Options
Timely put write in ActivisionBlizzard »

Timely put write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

14:55
11/15/18
11/15
14:55
11/15/18
14:55
General news
Trump Fed Board nominee Michelle Bowman was confirmed »

Trump Fed Board nominee…

14:55
11/15/18
11/15
14:55
11/15/18
14:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MFSF

MutualFirst Financial

$35.64

0.64 (1.83%)

14:53
11/15/18
11/15
14:53
11/15/18
14:53
Hot Stocks
MutualFirst Financial increases dividend 11% »

MutualFirst Financial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.